HY-154779 Search Results


ys49  (MedChemExpress)
93
MedChemExpress ys49
Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = RCGD423 (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = <t>YS49</t> (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.
Ys49, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ys49/product/MedChemExpress
Average 93 stars, based on 1 article reviews
ys49 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
ys 49  (MedChemExpress)
94
MedChemExpress ys 49
Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = RCGD423 (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = <t>YS49</t> (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.
Ys 49, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ys 49/product/MedChemExpress
Average 94 stars, based on 1 article reviews
ys 49 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = RCGD423 (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = YS49 (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.

Journal: Cancers

Article Title: Conversion of Osteoclasts into Bone-Protective, Tumor-Suppressing Cells

doi: 10.3390/cancers13225593

Figure Lengend Snippet: Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = RCGD423 (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = YS49 (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.

Article Snippet: RAW264.7 pre-osteoclast cells, MC3T3 osteoblasts, MSCs, and MLO-A5 osteocyte-like cells were treated with 0.5 µM of NSC228155 (Cayman, Ann Arbor, MI, USA), 20 µM of RCGD423 (Tocris, Minneapolis, MN, USA), 20 µM of m-3M3FBS (Tocris), 20 µM of CW008 (Tocris), 10 µM of OAC2 (MCE, Monmouth Junction, NJ, USA), 50µM of YS49 (MCE), and 0.2 µM of BML284 (Santa Cruz Biotechnology, Dallas, TX, USA) for 1 day.

Techniques: Control, Derivative Assay